IBDEI0BP ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5157,2)
 ;;=^86127
 ;;^UTILITY(U,$J,358.3,5158,0)
 ;;=277.30^^25^295^2
 ;;^UTILITY(U,$J,358.3,5158,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5158,1,2,0)
 ;;=2^277.30
 ;;^UTILITY(U,$J,358.3,5158,1,5,0)
 ;;=5^Amyloidosis NOS
 ;;^UTILITY(U,$J,358.3,5158,2)
 ;;=^334185
 ;;^UTILITY(U,$J,358.3,5159,0)
 ;;=136.1^^25^296^1
 ;;^UTILITY(U,$J,358.3,5159,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5159,1,2,0)
 ;;=2^136.1
 ;;^UTILITY(U,$J,358.3,5159,1,5,0)
 ;;=5^Behcet's Syndrome
 ;;^UTILITY(U,$J,358.3,5159,2)
 ;;=^13205
 ;;^UTILITY(U,$J,358.3,5160,0)
 ;;=705.89^^25^296^2
 ;;^UTILITY(U,$J,358.3,5160,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5160,1,2,0)
 ;;=2^705.89
 ;;^UTILITY(U,$J,358.3,5160,1,5,0)
 ;;=5^Bromhidrosis
 ;;^UTILITY(U,$J,358.3,5160,2)
 ;;=^271930
 ;;^UTILITY(U,$J,358.3,5161,0)
 ;;=700.^^25^297^7
 ;;^UTILITY(U,$J,358.3,5161,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5161,1,2,0)
 ;;=2^700.
 ;;^UTILITY(U,$J,358.3,5161,1,5,0)
 ;;=5^Corns And Callosities
 ;;^UTILITY(U,$J,358.3,5161,2)
 ;;=^18351
 ;;^UTILITY(U,$J,358.3,5162,0)
 ;;=709.09^^25^297^2
 ;;^UTILITY(U,$J,358.3,5162,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5162,1,2,0)
 ;;=2^709.09
 ;;^UTILITY(U,$J,358.3,5162,1,5,0)
 ;;=5^Cafe au lait spot
 ;;^UTILITY(U,$J,358.3,5162,2)
 ;;=^303313
 ;;^UTILITY(U,$J,358.3,5163,0)
 ;;=709.3^^25^297^3
 ;;^UTILITY(U,$J,358.3,5163,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5163,1,2,0)
 ;;=2^709.3
 ;;^UTILITY(U,$J,358.3,5163,1,5,0)
 ;;=5^Calcinosis,Skin
 ;;^UTILITY(U,$J,358.3,5163,2)
 ;;=^31460
 ;;^UTILITY(U,$J,358.3,5164,0)
 ;;=380.00^^25^297^4
 ;;^UTILITY(U,$J,358.3,5164,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5164,1,2,0)
 ;;=2^380.00
 ;;^UTILITY(U,$J,358.3,5164,1,5,0)
 ;;=5^Chondrodermatitis Nodularis Helicis
 ;;^UTILITY(U,$J,358.3,5164,2)
 ;;=^269337
 ;;^UTILITY(U,$J,358.3,5165,0)
 ;;=706.2^^25^297^8
 ;;^UTILITY(U,$J,358.3,5165,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5165,1,2,0)
 ;;=2^706.2
 ;;^UTILITY(U,$J,358.3,5165,1,5,0)
 ;;=5^Cyst,Epidermal
 ;;^UTILITY(U,$J,358.3,5165,2)
 ;;=^41304
 ;;^UTILITY(U,$J,358.3,5166,0)
 ;;=078.11^^25^297^6
 ;;^UTILITY(U,$J,358.3,5166,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5166,1,2,0)
 ;;=2^078.11
 ;;^UTILITY(U,$J,358.3,5166,1,5,0)
 ;;=5^Condyloma NOS
 ;;^UTILITY(U,$J,358.3,5166,2)
 ;;=^295788
 ;;^UTILITY(U,$J,358.3,5167,0)
 ;;=710.1^^25^297^1
 ;;^UTILITY(U,$J,358.3,5167,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5167,1,2,0)
 ;;=2^710.1
 ;;^UTILITY(U,$J,358.3,5167,1,5,0)
 ;;=5^CRST Syndrome
 ;;^UTILITY(U,$J,358.3,5167,2)
 ;;=^108590
 ;;^UTILITY(U,$J,358.3,5168,0)
 ;;=078.11^^25^297^5
 ;;^UTILITY(U,$J,358.3,5168,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5168,1,2,0)
 ;;=2^078.11
 ;;^UTILITY(U,$J,358.3,5168,1,5,0)
 ;;=5^Condyloma Accuminatum
 ;;^UTILITY(U,$J,358.3,5168,2)
 ;;=^295788
 ;;^UTILITY(U,$J,358.3,5169,0)
 ;;=216.8^^25^298^1
 ;;^UTILITY(U,$J,358.3,5169,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5169,1,2,0)
 ;;=2^216.8
 ;;^UTILITY(U,$J,358.3,5169,1,5,0)
 ;;=5^Dermatofibroma
 ;;^UTILITY(U,$J,358.3,5169,2)
 ;;=^267637
 ;;^UTILITY(U,$J,358.3,5170,0)
 ;;=710.3^^25^298^3
 ;;^UTILITY(U,$J,358.3,5170,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5170,1,2,0)
 ;;=2^710.3
 ;;^UTILITY(U,$J,358.3,5170,1,5,0)
 ;;=5^Dermatomyositis
 ;;^UTILITY(U,$J,358.3,5170,2)
 ;;=^33162
 ;;^UTILITY(U,$J,358.3,5171,0)
 ;;=709.00^^25^298^5
 ;;^UTILITY(U,$J,358.3,5171,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5171,1,2,0)
 ;;=2^709.00
 ;;^UTILITY(U,$J,358.3,5171,1,5,0)
 ;;=5^Dyschromia
 ;;^UTILITY(U,$J,358.3,5171,2)
 ;;=^37473
 ;;^UTILITY(U,$J,358.3,5172,0)
 ;;=709.9^^25^298^4
 ;;
 ;;$END ROU IBDEI0BP
